Clinical Trial

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
Protocol Amendment History 7 changes
notable Trial sites reduced: 341 -> 337 locations 2026-08-15
notable Trial sites expanded: 332 -> 340 locations 2026-06-24
notable Trial sites expanded: 305 -> 329 locations 2026-05-29
notable Trial sites expanded: 302 -> 305 locations 2026-05-23
notable Trial sites expanded: 295 -> 300 locations 2026-05-06
notable Trial sites expanded: 253 -> 295 locations 2026-04-28
notable Trial sites expanded: 188 -> 253 locations 2026-03-31
Trial Details
NCT Number NCT07028853
Lead Sponsor Pfizer
Conditions Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Enrollment 1,000 participants
Start Date 2025-09-28
Primary Completion 2028-09-12 (estimated)
Study Completion 2034-12-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-14